We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Anticancer Genes Planted into Normal Brain Tissues Eliminate Nearby Tumors

By LabMedica International staff writers
Posted on 13 Oct 2008
Cancer researchers have successfully eliminated brain tumors in laboratory mice by inserting the gene for interferon-beta (IFN-beta) into normal brain cells surrounding the tumors.

Glioblastoma multiforme (GBM) is a devastating form of brain cancer for which there is no effective treatment. More...
In recent years, attempts have been made to treat this disease by gene therapy, the introduction of various types of toxic genes directly into the tumor. However, this technique has proven unsuccessful because it has not been possible to insert the genes into 100% of the tumor cells. Following the death of the transfected cells, surviving tumor cells are free to grow and spread. Repeated injections of anti-cancer genes generally stimulate production of antibodies that render the treatment ineffective.
Investigators at Massachusetts General Hospital (Charlestown, MA, USA) have taken a different approach. They reasoned that by injecting the gene for the anti-cancer protein INF-beta into the normal tissues surrounding the tumor, they would create a barrier preventing the tumor from spreading. Eventually the INF-beta secreted by the nearby tissues would destroy the tumor itself.

Results published in the October 2008 issue of the journal Molecular Therapy showed that this method could work. They showed that a single injection of adeno-associated virus (AAV) vector encoding IFN-beta caused significant shrinkage of brain tumors in a mouse model within four days. After two weeks, the tumors disappeared completely.

Since interferon-beta treatment is known to have side effects, it will be necessary to identify any toxicity caused by long-term secretion of the protein in the brain and develop preventive strategies, such as turning off the introduced genes.

"These results are particularly important as we build on our understanding of the microenvironments that allow tumors to grow and spread,” explained senior author Dr. Miguel Sena-Esteves, assistant professor of neurology at Massachusetts General Hospital. "The therapeutic principle of genetically engineering normal brain tissue could be used to manipulate proteins required for that microenvironment, preventing tumors from migrating within the patients brain and escaping other therapies. We had hypothesized that genetically engineering normal tissue surrounding a tumor could create a zone of resistance – a microenvironment that prevents the growth or spread of the tumor. This proof of principle study shows that this could be a highly effective approach, although there are many additional questions that need to be investigated.”

Related Links:

Massachusetts General Hospital


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.